2019-20 National Advisory Committee on Immunization (NACI) workplan

PDF version (292 KB, 2 pages)

Preamble

The following represents the National Advisory Committee on Immunization's planned work for the 2019-2020 fiscal year (April 2019 to March 2020). These projects will not necessarily be completed within the fiscal year. This workplan may be reassessed based on emerging public health needs. Triggers for the activation of Working Groups (WGs) and the development of new NACI guidance documents, or the adoption of new priorities may include the following:

Workplan

Initiative

Issue(s)

Triggers

Expected date of completion*

Ebola Virus Disease

Interim pre-market guidance on domestic use of stockpiled investigational vaccine for ring vaccination strategy in event of imported cases, post-market guidance to follow in later years

New vaccine

Q2 2019 for interim guidance

Hepatitis A

Consider a universal hepatitis A vaccine schedule, including 1-dose option

Recommendation adoption by reputable organization

2021

Measles, Mumps, Rubella (MMR)

Consider additional dose of mumps-containing vaccine in outbreaks

Changes in disease epidemiology

2019-20

Full CIG chapter update for Measles, Mumps and Rubella due

CIG chapter reviews due

2019-20

Pertussis

Optimal timing of adult and adolescent Tdap boosters, including Td intervals

P/T programmatic concerns

2020

Pneumococcal

Evaluation of preferential PCV13 recommendation for routine infant programs

Recommendation adoption by reputable organization

2020

Rabies

Updated guidance on rabies vaccine PrEP and PEP in context of new guidance from WHO

Recommendation adoption by reputable organization

2020

Full CIG chapter review due

CIG chapter review due

2020

Respiratory Syncytial Virus (RSV)

Review/update NACI guidance on Palivizumab

Recommendation adoption by reputable organization

2019-20

CIG - chapter creation

 

2019-20

Seasonal Influenza

Seasonal influenza

New vaccine

2020-21

New Products: quadrivalent influenza vaccines

New vaccine

2020-21 (dependant on NOC)

Repeated vaccination

P/T programmatic concerns

2020

CIG: Part 1 (Key immunization information)

Routine chapter updates (6): Immunization in Canada. Benefits of Immunization, National Guidelines for Immunization Practices, Communicating Effectively about Immunization, Principles of Vaccine Interchangeability, Blood Products, Human Immune Globulin and Timing of Immunization

CIG chapter reviews due

2019-20

CIG : 
Part 2: Vaccine Safety

Routine chapter updates (3)

CIG chapter reviews overdue

2019-20

CIG: Part 3: Special Populations

Routine chapter updates (6): Immunization of Adults, Immunization of Persons with Inadequate Immunization Records, Immunization of Infants Born Prematurely, Immunization of Patients in Healthcare Institutions, Immunization of Persons New to Canada, Immunization of Workers

CIG chapter reviews overdue

2019-20

CIG: Part 4: Active Vaccines

Routine chapter updates (12): BCG, Diphtheria, Hib, MMR, Polio, Rabies, Smallpox, Tetanus, YF, JE

CIG chapter reviews due and some overdue

2019-20

Ethics, Equity, Feasibility, Acceptability (EEFA)

Incorporation into NACI process: EEFA

Recommendation adoption by reputable organization

2019

NACI economics framework

Incorporation into NACI process: economics framework

Recommendation adoption by reputable organization

2020

Economic guidelines

Incorporation into NACI process: economic guidelines

Recommendation adoption by reputable organization

2021

*Please note that this workplan is evergreen. As new products and indications are authorized or new information becomes available, workplan items may be added for consideration and priorities may change.

Abbreviations:

NACI

National Advisory Committee on Immunization

BCG

Bacillus Calmette-Guérin

CATMAT

Committee to Advise on Tropical Medicine and Travel

CCDR

Canada Communicable Disease Report

CIC

Canadian Immunization Committee

CIG

Canadian Immunization Guide

CPS

Canadian Paediatric Society

EEFA

Ethics, Equity, Feasibility, Acceptability

FY

Fiscal year (April 1 - March 31)

Hib

Haemophilus influenzae type b

JE

Japanese encephalitis

NoC

Notice of compliance

PCV13

Pneumococcal conjugate vaccine

PEP

Post-exposure prophylaxis

PrEP

Pre-exposure prophylaxis

P/Ts

Provinces and territories

QIV

Quadrivalent influenza vaccine

SOGC

Society of Obstetricians and Surgeons of Canada

Td

Tetanus and diphtheria vaccine

Tdap

Tetanus, diphtheria and pertussis vaccine

TIV

Trivalent influenza vaccine

TOR

Terms of reference

WG

Working group

WHO

World Health Organization

YF

Yellow fever

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: